Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

Shots: Anas spoke about revenue cycle management in the healthcare sector and the traditional challenges in the healthcare RCM He also elaborated on how the evolving technologies can help to overcome the challenges in healthcare revenue cycle management The interview shows how Santechture is developing smart AI-based and cloud-based solutions to help healthcare providers develop…

BySenior EditorJune 2, 2023

INSIGHTS+

Top Performing Drug of 2021 – Trulicity (February Edition)

Active Ingredient: dulaglutide Dosage Forms & Strengths: Injection: 0.75 mg/0.5 mL, 1.5 mg/0.5 mL, 3 mg/0.5 mL, 4.5 mg/0.5 mL solution in a single-dose pen Mechanism of Action: GLP-1 receptor agonist First Approval: US (Sep 18, 2014), EU (Nov 25, 2014) Revenue Analysis1 Trulicity is used for the treatment of type 2 diabetes and to reduce the risk…

BySenior EditorFebruary 22, 2023

EVENTS

Pharma IPR Conference 2023: The 12th Annual Pharma Intellectual Property Rights

The 12th edition of the Pharma IPR Conference organized by Informa Markets will be held from 1-3 March 2023 in Mumbai. This is the only conference in India's pharmaceutical industry that focuses on Intellectual Property. The aim of this conference is to bring together all stakeholders in the pharma sector to discuss and deliberate on…

BySenior EditorJanuary 30, 2023

INSIGHTS+

Top Performing Drug of 2021 – Imbruvica (January Edition)

Active Ingredient: Ibrutinib Dosage Forms & Strengths: Capsules: 70 mg and 140 mg Tablets: 140 mg, 280 mg, 420 mg, and 560 mg Mechanism of Action: Bruton's tyrosine kinase Inhibitor (BTKi) First Approval: US (13 Nov 2013), EU (Oct 2014)  Revenue Analysis Imbruvica is an oral therapy that inhibits a protein called Bruton's tyrosine kinase. Imbruvica was one…

BySenior EditorJanuary 25, 2023

INSIGHTS+

Top Performing Drug of 2021 – Opdivo (December Edition)

Active Ingredient: Nivolumab Strength: 40 mg/4 mL, 100 mg/10 mL, & 240 mg/24 mL solution in a single-dose vial Dosage Form: Injection Mechanism of Action: Programmed cell death-1 receptor antagonists (PD-1) First Approval: US (22 Dec 2014), EU (19 Jun 2015)  Revenue Analysis of Opdivo BMS’ Opdivo gives tough competition to other drugs in the…

BySenior EditorDecember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Xarelto (November Edition)

Active Ingredient: rivaroxaban Strength: 2.5 mg, 10 mg, 15 mg, and 20 mg Dosage Form: Tablets Mechanism of Action: Factor Xa inhibitors First Approval: US (1 Jul 2011), EU (30 Sep 2008) Revenue Analysis of Xarelto1 Xarelto has been an important driver of the revenue generated from the cardiovascular portfolio of Janssen. The blood thinner showed an increase of 4%…

BySenior EditorNovember 24, 2022

INSIGHTS+

Top Performing Drug of 2021 – Biktarvy (October Edition)

Active Ingredient: bictegravir, emtricitabine, and tenofovir alafenamide Strength: 50 mg of BIC, 200 mg of FTC, and 25 mg of TAF/ 30 mg of BIC, 120 mg of FTC, and 15 mg of TAF Dosage Form: Tablet Mechanism of Action: HIV reverse transcriptase inhibitors First Approval: US (07 Feb 2018), EU (25 Jun 2018) Revenue1 Gilead's HIV drug, Biktarvy has…

BySenior EditorOctober 27, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eylea (September Edition)

Active Ingredient: Aflibercept Strength: 2 mg (0.05 mL) Dosage Form: Injection (intravitreal) Mechanism of Action: VEGF-A and PlGF inhibitors First Approval: US (18 Nov 2011), EU (27 Nov 2012) Revenue1 EYLEA net sales represent a significant portion of the total revenues for both Regeneron and Bayer. Both companies jointly commercialize the product Regeneron records net product sales of EYLEA in…

BySenior EditorSeptember 22, 2022

INSIGHTS+

Top Performing Drug of 2021 – Stelara (August Edition)

Active Ingredients: Ustekinumab Strength: 45 mg/0.5 mL or 90 mg/mL (SC), 130 mg/26 mL (IV) Dosage Form: Injection Mechanism of Action: Interleukin 12 & 23 inhibitor First Approval: US (25 Sep, 2009), EU (16 Jan, 2009) Revenue1 Stelara is the leading blockbuster drug of Johnson & Johnson. Stelara contributed 9.7% of the Company's total revenues for 2021. Stelara up took…

BySenior EditorAugust 25, 2022

INSIGHTS+

Top Performing Drug of 2021 – Eliquis (July Edition)

Active Ingredients: Apixaban Strength: 2.5 mg and 5 mg Dosage Form: Tablet Mechanism of Action: Factor Xa inhibitors First Approval: US (Dec 28, 2012), EU (May 18, 2011) Revenue1 Eliquis is a leading novel oral anticoagulant of BMS. The revenue for BMS continued to grow due to Eliquis and other recently launched new products. BMS and Pfizer jointly develop and…

BySenior EditorJuly 28, 2022

Anas Batikhi, Founder & CEO at Santechture Shares on RCM-Tech, A Necessity in The Healthcare Industry

Top Performing Drug of 2021 – Trulicity (February Edition)

Pharma IPR Conference 2023: The 12th Annual Pharma Intellectual Property Rights

Top Performing Drug of 2021 – Imbruvica (January Edition)

Top Performing Drug of 2021 – Opdivo (December Edition)

Top Performing Drug of 2021 – Xarelto (November Edition)

Top Performing Drug of 2021 – Biktarvy (October Edition)

Top Performing Drug of 2021 – Stelara (August Edition)

Top Performing Drug of 2021 – Eliquis (July Edition)

Contact US

OUR INFORMATION

FOLLOW US